Article: Nicotinamide Riboside and Pterostilbene Increase NAD+ Levels in Patients with Acute Kidney Injury: Clinical Findings

Aug 13, 2020 Clinical Kidney Disease Kidney Health Pharmacokinetic/Safety

Nicotinamide Riboside and Pterostilbene Increase NAD+ Levels in Patients with Acute Kidney Injury: Clinical Findings

Objectives

To evaluate the effects of escalating doses of nicotinamide riboside and pterostilbene (NRPT) on blood NAD+ levels and safety outcomes in patients hospitalized with acute kidney injury (AKI), with the long-term goal of assessing NRPT as a potential treatment for AKI.

Journal

BMC Nephrology

Key Outcomes

NRPT supplementation reversed AKI-induced NAD+ decline and significantly increased NAD+ levels across all doses.
Short-term NRPT was well-tolerated at all doses and did not adversely affect kidney function, a crucial finding for AKI patients.

Duration

2 days per step (8 days total)

Dose

Step 1: 500 mg NR + 100 mg PT
Step 2: 1000 mg NR + 200 mg PT
Step 3: 1500 mg NR + 300 mg PT
Step 4: 2000 mg NR + 400 mg PT

Study Design

Randomized, double-blind, placebo-controlled, dose-escalation pilot study in 24 hospitalized patients with AKI

See Published Study

Cardiovascular Disease

Nicotinamide Riboside Supplementation Reduces Inflammation in Heart Failure Patients: Clinical Findings

Objectives To investigate the mechanistic link between mitochondrial dysfunction and inflammatory activation in peripheral blood mononuclear cells (PBMCs), and the potential anti-inflammatory effe...